SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Evofem Biosciences,
Inc., (NASDAQ: EVFM) today announced it will participate in
the Piper Sandler 32nd Annual Virtual Healthcare Conference,
taking place virtually November 30 through
December 3, 2020.
In advance of the virtual conference and investor meetings, a
pre-recorded fireside chat with Saundra
Pelletier, CEO of Evofem Biosciences, will be made available
on Monday, November 23 at
10:00 AM Eastern Time.
Interested parties may access the fireside chat by visiting
the
Investors section of the Evofem Biosciences website
at www.evofem.com, under the Events and
Presentations tab.
About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage
biopharmaceutical company committed to developing and
commercializing innovative products to address unmet needs in
women's sexual and reproductive health, including hormone-free,
woman-controlled contraception and protection from certain sexually
transmitted infections (STIs). The Company's first commercial
product, Phexxi® (lactic acid, citric acid and potassium
bitartrate), is the first and only hormone-free, prescription
vaginal gel approved in the United States for the
prevention of pregnancy. The Company is evaluating EVO100 in
a Phase 3 clinical trial, 'EVOGUARD,' for the prevention
of urogenital Chlamydia trachomatis and Neisseria
gonorrhoeae infection in women. For more information,
please visit www.evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences,
Inc.
Investor Relations Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
Media Contact
Ellen
Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com
Mobile: (718) 490-3248
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-participate-in-piper-sandler-32nd-annual-virtual-healthcare-conference-301178010.html
SOURCE Evofem Biosciences, Inc.